Enzo ALX-522-001-3010 FasL (soluble) (human), (recombinant) (3 x 10 µg)

APO-1L, CD95L, CD178, TNFSF 6

ELISA: binds to Fas receptor at 1-100 ng/ml.

Kills Jurkat cells in the absence of a cross-linker. Cross-linking enhancer (see Set Prod. No. ALX-850-014) increases the activity of rhsFasL approx. 50-fold.
Attention: Results using sFasL may differ from those obtained with agonistic antibodies!

0.1mg/ml after reconstitution.

<0.1EU/µg purified protein (LAL test; Associates of Cape Cod).

Lyophilized. Contains PBS.

~32kDa (non-glycosylated), ~35kDa (glycosylated) (SDS-PAGE).

≥95% (SDS-PAGE)

Purified by multi-step chromatography.

Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum.

Produced in HEK 293 cells. The extracellular domain of human FasL (APO-1L; CD95L; CD178) (aa 103-281) is fused at the N-terminus to a linker peptide (26 aa) and a FLAG^®-tag. Glycosylation of rhsFasL is similar to that of natural human FasL.

Binds to human, mouse and rat Fas (CD95; APO-1).

Historical lots have shown that FasL kills Jurkat cells at concentrations of >10ng/ml in the absence of a cross-linker. Historical lots have also shown an ED₅₀ of 50ng/ml (A20 cells).

P48023

Stable for at least 6 months after receipt when stored at -20°C.

Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.

-20°C

Blue Ice